跳至主要内容
临床试验/NCT05518240
NCT05518240招募中不适用

Comparison of Solitaire to Embotrap to Treat Large Vessel Occlusion in Acute Ischemic Stroke (SOLTRAP Study)

WellStar Health System2 个研究点 分布在 1 个国家目标入组 418 人开始时间: 2022年8月24日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
418
试验地点
2
主要终点
Severity of Disability

研究概览

简要总结

The primary aim of this study is to assess if there is a difference in first pass reperfusion between the two devices. This is a randomized prospective study to assess if there is a difference in first pass reperfusion at two centers with large mechanical thrombectomy volumes. Data will also be collected on time-to treatment, outcomes and hemorrhagic complications.

详细描述

The SOLTRAP Study is an investigator initiated two hospital study designed to assess the procedural success and clinical outcomes associated with mechanical thrombectomy using the Medtronic Solitaire Device and the Cerenovous Embotrap device. Both devices are FDA approved for this indication of removal of a thrombus for patients suffering from stroke secondary to a large vessel occlusion.

Data collected will include device used during the procedure, mechanical thrombectomy techniques, time from onset to imaging, imaging to puncture, and overall time from onset to reperfusion as well as quality of life at 90 days post stroke.

The study will enroll up to 418 subjects and will be conducted at Wellstar North Fulton Hospital and Wellstar Kennestone Hospital. The devices will have regulatory authorization to be on the market in the geographic location of both sites.

The duration of the Registry protocol is approximately 24 months

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who experienced acute ischemic stroke (AIS), eligible for restoration of blood flow using a Solitaire or Embotrap device to remove thrombus from the neurovasculature
  • Occlusion of intracranial cerebral circulation vessel involving the M1, M2 MCA or ICA-T (Tandem occlusions will be enrolled)
  • Subject or subject's legally authorized representative (LAR) has signed the informed consent form prior to or within 72 hours post-procedure
  • Subject is willing to comply with the protocol follow-up requirements
  • The intended technique and treated technique must be one of the following techniques for the first thrombectomy pass in the neurovasculature per Instructions for Use (IFU).

排除标准

  • 1.The subject can participate in another clinical trial if the study does not impact the endpoints defined in this protocol given this is a data collection trial. Patients who are unable to comply wit the 90 day follow up in person or via telephone will be excluded from the study.

结局指标

主要结局

Severity of Disability

时间窗: Day 90 (+14)

assessed by mRS with a good functional outcome defined as mRS of 0-2 for each technique

次要结局

  • Excellent functional outcome(Day 90 (+14))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Benjamin Zussman, MD

Comparison of Solitaire to Embotrap to treat Large Vessel Occlusion in Acute Ischemic stroke (SOLTRAP Study)

WellStar Health System

研究点 (2)

Loading locations...

相似试验

Comparison of Solitaire to Embotrap to Treat Large... | 临床试验